Phase 3 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with non-small cell lung cancer (NSCLC)
- People aged 18 or older who have had surgery to remove the cancer and where laboratory testing of the removed tissue confirmed that the cancer had spread to nearby lymph nodes
- People who are able to receive platinum-based chemotherapy as part of their treatment
- People who are in reasonably good general health, as measured by standard medical scoring tools (confirm with trial site for exact score requirements)
- People who are sufficiently proficient in the Mandarin language
Who may not be able to join:
- People who have previously had radiation treatment to the brain
- People who have another active cancer diagnosis, other than a specific type of minor skin cancer (basal cell carcinoma) or a very early-stage cervical condition (cervical carcinoma in situ)
- People whose scans show that the cancer has spread to the brain
- People with clinical signs that the cancer has spread to other parts of the body outside the brain
- People who have had an allergic reaction to the contrast dye used in MRI scans
- People with serious medical or mental health conditions
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chi-Cheng Yang, Ph.D., Chang Gung University
Phone: 886-988378478
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
time to the development of brain metastasis/metastases (BM), irrespective of the absence of active neurological symptoms
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.